Search Within

Helena Alexandra Yu

  1. "American Society of Clinical Oncology"
Formats
  1. Meeting Abstract (65)
  2. Journal Article (12)
  3. Review (2)
  4. Editorial (1)
Groups
  1. Department of Medicine (80)
  2. Solid Tumor Oncology Division (80)
  3. Thoracic Oncology (80)
  4. GSK Faculty (36)
  5. Department of Pathology and Laboratory Medicine (30)
  6. Human Oncology and Pathogenesis Program (30)

More Groups

People
  1. Gregory Riely (35)
  2. Mark Kris (34)
  3. Marc Ladanyi (21)
  4. Charles Rudin (16)
  5. Maria Arcila (15)
  6. Alexander Drilon (13)

More People

Years
  1. 2024 (12)
  2. 2023 (8)
  3. 2022 (10)
  4. 2021 (7)
  5. 2020 (3)
  6. 2019 (7)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. JCO Precision Oncology (5)
  3. American Society of Clinical Oncology Educational Book (2)
Publishers
  1. American Society of Clinical Oncology (80)

Results (80)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer
    Journal Article

    Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK plus non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Jayakrishnan, R.; Nassar, A.; Shepherd, F. A.; Lin, J. J.; Lin, S. H.; Shakya, P.; Dilling, T. J.; Bar, J.; Grohe, C.; Gupta, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, L.; Wei, Y.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer
    Meeting Abstract

    Quintanal-Villalonga, A.; Kawasaki, K.; Redin, E.; Rakhade, S.; Durani, V.; Sabet, A.; Karthaus, W.; Zaidi, S.; Zhan, Y. A.; Manoj, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations
    Meeting Abstract

    Chen, M. F.; Rakhade, S.; Quintanal-Villalonga, A.; Lee, J.; Forsythe, B.; Moses, K. A.; Ahn, L. S. H.; Pupo, A.; Falcon, C. J.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Signatures of early plasticity in the histological transformation of lung cancer
    Meeting Abstract

    Rakhade, S.; Chen, M. F.; Quintanal-Villalonga, A.; Sabet, A.; Manoj, P.; Chaudhary, O.; Xu, T.; Masilionis, I.; Falcon, C. J.; Egger, J. V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC
    Meeting Abstract

    Thummalapalli, R.; Muldoon, D.; Febres-Aldana, C. A.; Falcon, C. J.; Pupo, A.; Bandlamudi, C.; Berger, M. F.; Yu, H. A.; Riely, G. J.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Meeting Abstract

    Nishio, M.; Yu, H. A.; Besse, B.; Cheng, Y.; Tan, D. S. W.; Wei, L.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save